Ignite Creation Date:
2024-05-06 @ 12:42 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03828955
Status:
COMPLETED
Last Update Posted:
2021-05-24
First Post:
2019-02-01
Brief Title:
Evaluation of Soybean Peptides Product on Regulation of Blood Pressure Effect in Humans
Sponsor:
Chung Shan Medical University
Organization:
Chung Shan Medical University
Study Overview
Official Title:
Evaluation of Soybean Peptides Product on Regulation of Blood Pressure Effect by Clinical Trial
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension Overall soybean peptide consumption for 8 weeks could successfully reduce mean diastolic and systolic BP through the suppression of Angiotensin-converting enzyme ACE linked to downstream suppression of angiotensin II formation which further decreases the sympathetic outflow that leads to hypertension
Detailed Description:
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension Thirty subjects with systolic blood pressure SBP between 120 and 159 mm Hg andor diastolic blood pressure DBP between 80 and 99 mm Hg were randomized to ingest 2 bags of soybean peptides or placebo per day for 8 weeks of a stage Anthropometric measurements blood pressure body weight body fat and blood biochemical markers including fasting blood glucose FBG albumin total cholesterol TC triglyceride TG HDL-C LDL-C creatinine Cr blood urea nitrogen BUN AST ALT were examined every four weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None